Next Article in Journal
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Next Article in Special Issue
Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs
Previous Article in Journal
Vimentin Intermediate Filaments as Potential Target for Cancer Treatment
Previous Article in Special Issue
Deregulated NKL Homeobox Genes in B-Cell Lymphoma
Open AccessReview

Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?

Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, Italy
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 185; https://doi.org/10.3390/cancers12010185
Received: 22 November 2019 / Revised: 7 January 2020 / Accepted: 9 January 2020 / Published: 11 January 2020
(This article belongs to the Special Issue Recent Advances in the Pathogenesis of B Cell Malignancies)
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone—R-CHOP), which allows a 60% overall survival (OS) rate, but up to 40% of patients experience relapse or refractory (R/R) disease. With the purpose of searching for new clinical parameters and biomarkers helping to make a better DLBCL patient characterization and stratification, in the last years a series of large discovery genomic and transcriptomic studies has been conducted, generating a wealth of information that needs to be put in order. We reviewed these researches, trying ultimately to understand if there are bases offering a roadmap toward personalized and precision medicine also for DLBCL. View Full-Text
Keywords: diffuse large B-cell lymphoma (DLBCL); COO classification; next-generation sequencing (NGS); biomarker; liquid biopsy; targeted therapy diffuse large B-cell lymphoma (DLBCL); COO classification; next-generation sequencing (NGS); biomarker; liquid biopsy; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Coccaro, N.; Anelli, L.; Zagaria, A.; Perrone, T.; Specchia, G.; Albano, F. Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? Cancers 2020, 12, 185.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop